Story perspectives

Trump's Order Aims to Boost Transparency in Drug Ads

9/14/2025

39 9

Center

Trump Advocates Transparency

President Trump's administration seeks increased transparency in pharmaceutical advertising, affecting drugmakers and media revenue.
An executive order requires more disclosure of side effects in drug ads without banning them.
Experts caution this could disrupt the $5 billion revenue from such ads in 2024.
Legal challenges are expected, as commercial speech is protected but can be regulated.
The administration aims to enhance public trust and informed patient choices regarding medications.

Left

FDA Targets Misleading Ads

The FDA is ramping up enforcement against misleading pharmaceutical advertisements, issuing about 100 cease-and-desist letters.
New regulations aim to eliminate loopholes that permit the omission of safety information in ads, a practice that has risen since 1997.
Bipartisan lawmakers, including Senators Sanders and King, are pushing for reforms in direct-to-consumer advertising due to health and financial concerns.
The FDA's strategy focuses on restoring accountability in drug marketing and reallocating funds from advertising to reducing drug prices.
Critics claim that current advertisements distort the physician-patient relationship and encourage unnecessary medication use.

1 of 2

Trump Advocates Transparency

President Trump's administration seeks increased transparency in pharmaceutical advertising, affecting drugmakers and media revenue.
An executive order requires more disclosure of side effects in drug ads without banning them.
Experts caution this could disrupt the $5 billion revenue from such ads in 2024.
Legal challenges are expected, as commercial speech is protected but can be regulated.
The administration aims to enhance public trust and informed patient choices regarding medications.

1 / 2